Citi raised the firm’s price target on Kymera Therapeutics (KYMR) to $80 from $60 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Kymera Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating
- Kymera Therapeutics participates in a conference call with JPMorgan
- Kymera Therapeutics price target raised to $63 from $53 at Oppenheimer
- Kymera Therapeutics price target raised to $68 from $53 at Truist